Annual General Meeting and Board Changes

RNS Number : 0207G

Oxford Biomedica PLC

05 May 2011

 

FOR IMMEDIATE RELEASE

5 May 2011

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING AND BOARD CHANGES

Oxford, UK - 5 May 2011: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

·     Resolution 6: to empower the Directors to allot equity securities, pursuant to section 551 of the 
Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £3,149,585 with a further aggregate nominal amount of £3,149,585 authorised in connection with a rights issue, or where applicable, other proportionate offer;

·     Resolution 7: to empower the Directors to allot equity securities for cash, pursuant to section 
570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;

·     Resolution 8: to extend the Oxford BioMedica plc Share Option Scheme on its current terms for five years from 1 February 2012.

·     Resolution 9: to extend the Oxford BioMedica plc Long Term Incentive Plan on its current terms for five years from 1 February 2012.

·     Resolution 10: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting our website at www.oxfordbiomedica.co.uk

Certified copies of the document setting out the above resolutions passed at the 2011 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (03 May 2011) there were 944,875,557 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolutions
1	366,724,525	286,462	1,792,205	183,015	10,529	368,996,736	Passed
2	365,388,618	293,062	1,792,205	414,743	1,108,108	368,996,736	Passed
3	366,724,408	286,801	1,792,205	157,081	36,241	368,996,736	Passed
4	366,736,464	288,111	1,792,205	153,492	26,464	368,996,736	Passed
5	366,658,614	293,401	1,792,205	230,670	21,846	368,996,736	Passed
6	365,267,950	286,801	1,792,205	366,397	1,283,383	368,996,736	Passed
8	351,435,346	290,183	1,792,205	349,446	15,129,556	368,996,736	Passed
9	366,415,760	290,183	1,792,205	377,604	120,984	368,996,736	Passed
Special resolutions
7	366,346,547	278,363	1,792,205	494,941	84,680	368,996,736	Passed
10	364,696,687	287,818	1,792,205	2,200,628	19,398	368,996,736	Passed

As announced on 21 March 2011, at the AGM the Chairman, Dr Alan Kingsman, left the Board of Oxford BioMedica. Nick Rodgers, previously Non-Executive Director, Senior Independent Director and Deputy Chairman, has become Chairman.

In addition to these changes, Dr Andrew Heath, Non-Executive Director, will now become the Senior Independent Director and Deputy Chairman.  

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media/Financial Enquiries: Katja Toon/Emma Thompson/Amber Bielecka M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

RAGAAMBTMBAMBTB